

Peter J Whitehouse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12163260/publications.pdf>

Version: 2024-02-01

60
papers

7,008
citations

147726

31
h-index

155592

55
g-index

60
all docs

60
docs citations

60
times ranked

4454
citing authors

#	ARTICLE	IF	CITATIONS
1	Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. <i>Annals of Neurology</i> , 1981, 10, 122-126.	2.8	1,694
2	A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease. <i>New England Journal of Medicine</i> , 1992, 327, 1253-1259.	13.9	627
3	Nicotinic acetylcholine binding sites in Alzheimer's disease. <i>Brain Research</i> , 1986, 371, 146-151.	1.1	541
4	Basal forebrain neurons in the dementia of Parkinson disease. <i>Annals of Neurology</i> , 1983, 13, 243-248.	2.8	527
5	Disclosure of <i>APOE</i> Genotype for Risk of Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 245-254.	13.9	490
6	Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. <i>Nature</i> , 1986, 319, 593-595.	13.7	260
7	Changing perspectives regarding late-life dementia. <i>Nature Reviews Neurology</i> , 2009, 5, 649-658.	4.9	259
8	Aminergic systems in Alzheimer's disease and Parkinson's disease. <i>Annals of Neurology</i> , 1987, 22, 229-236.	2.8	230
9	Abnormalities of the nucleus basalis in Down's syndrome. <i>Annals of Neurology</i> , 1985, 18, 310-313.	2.8	196
10	The concept of subcortical and cortical dementia: Another look. <i>Annals of Neurology</i> , 1986, 19, 1-6.	2.8	195
11	Evaluation of Dementia. <i>New England Journal of Medicine</i> , 1996, 335, 330-336.	13.9	185
12	Loss of pedunculopontine neurons in progressive supranuclear palsy. <i>Annals of Neurology</i> , 1987, 22, 18-25.	2.8	181
13	Amyotrophic lateral sclerosis: Alterations in neurotransmitter receptors. <i>Annals of Neurology</i> , 1983, 14, 8-16.	2.8	151
14	Muscarinic and nicotinic cholinergic binding sites in alzheimer's disease cerebral cortex. <i>Brain Research</i> , 1987, 436, 62-68.	1.1	145
15	Assessment of Behavioral and Affective Symptoms in Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1990, 3, 21-30.	1.2	145
16	Fairhill Guidelines on Ethics of the Care of People With Alzheimer's Disease: A Clinical Summary*. <i>Journal of the American Geriatrics Society</i> , 1995, 43, 1423-1429.	1.3	108
17	Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. <i>Genetics in Medicine</i> , 2004, 6, 197-203.	1.1	101
18	Neurotransmitter receptor alterations in Huntington's disease: Autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. <i>Annals of Neurology</i> , 1985, 18, 202-210.	2.8	83

#	ARTICLE	IF	CITATIONS
19	Reasons for Seeking Genetic Susceptibility Testing Among First-Degree Relatives of People With Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2003, 17, 86-93.	0.6	82
20	Primary Degenerative Dementia Without Alzheimer Pathology. <i>Canadian Journal of Neurological Sciences</i> , 1986, 13, 462-470.	0.3	69
21	Cholinergic receptors in aging and Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1986, 10, 665-676.	2.5	68
22	Cellular pathology in Alzheimer's and Parkinson's diseases. <i>Trends in Neurosciences</i> , 1986, 9, 29-33.	4.2	67
23	Immunohistochemical study of neurons containing corticotropin-releasing factor in Alzheimer's disease. <i>Synapse</i> , 1987, 1, 405-410.	0.6	66
24	Corticotropin-Releasing Factor Receptors in Human Pituitary Gland: Autoradiographic Localization. <i>Neuroendocrinology</i> , 1985, 40, 419-422.	1.2	50
25	Abnormalities in Corticotropin-releasing Hormone (CRH) in Alzheimer's Disease and Other Human Disorders. <i>Annals of the New York Academy of Sciences</i> , 1987, 512, 237-247.	1.8	45
26	A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. <i>Genetics in Medicine</i> , 2018, 20, 132-141.	1.1	36
27	Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease. <i>Annals of Internal Medicine</i> , 2016, 164, 155.	2.0	34
28	Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease. <i>Brain Research</i> , 1987, 437, 355-359.	1.1	33
29	Bilateral changes in neocortical [3H]pirenzepine and [3H]oxotremorine-M binding following unilateral lesions of the rat nucleus basalis magnocellularis: an autoradiographic study. <i>Brain Research</i> , 1989, 483, 367-372.	1.1	33
30	Anthropological contributions to the understanding of age-related cognitive impairment. <i>Lancet Neurology</i> , The, 2005, 4, 320-326.	4.9	33
31	Antiaging Medicine and Mild Cognitive Impairment: Practice and Policy Issues for Geriatrics. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 1417-1422.	1.3	31
32	A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1222-1230.	0.4	28
33	Alzheimer's Dementia: Performance on parallel forms of the Dementia Assessment Battery. <i>Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology</i> , 1989, 11, 899-912.	1.4	26
34	Alteration of Phospholipase C α Protein Level and Specific Activity in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1995, 64, 2629-2634.	2.1	25
35	Ethical issues in early diagnosis and prevention of Alzheimer disease. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 101-108.	1.8	20
36	Describing the Dying Days of "Alzheimer's Disease". <i>Journal of Alzheimer's Disease</i> , 2011, 24, 11-13.	1.2	15

#	ARTICLE	IF	CITATIONS
37	Paying attention to acetylcholine: the key to wisdom and quality of life?. Progress in Brain Research, 2004, 145, 311-317.	0.9	12
38	Quality of life: The bridge from the cholinergic basal forebrain to cognitive science and bioethics. Journal of Alzheimer's Disease, 2006, 9, 447-453.	1.2	11
39	Parkinson's disease and Alzheimer's disease: New neurochemical parallels. Movement Disorders, 1989, 4, S57-S62.	2.2	10
40	Neurotransmitter receptors in amyotrophic lateral sclerosis: Possible relationship to sparing of eye movements. Annals of Neurology, 1985, 17, 518-518.	2.8	9
41	Alzheimer's Disease: Relationship of Cognition and Behavior to Neurochemistry. International Psychogeriatrics, 1992, 4, 71-78.	0.6	9
42	Van Rensselaer Potter: An Intellectual Memoir. Cambridge Quarterly of Healthcare Ethics, 2002, 11, 331-334.	0.5	9
43	Dysfunction and Death of Neurons in Human Degenerative Neurological Diseases and in Animal Models. Novartis Foundation Symposium, 1987, 126, 30-48.	1.2	9
44	Aberrant Phosphoinositide Metabolism in Alzheimer's Disease. Annals of the New York Academy of Sciences, 1993, 695, 46-49.	1.8	8
45	InterWell: an integrated school-based primary care model. London Journal of Primary Care, 2013, 5, 106-110.	0.9	8
46	A Tale of Two Reports: What Recent Publications from the Alzheimer's Association and Institute of Medicine say about the State of the Field. Journal of Alzheimer's Disease, 2015, 49, 21-25.	1.2	8
47	Pharmacotherapy for Alzheimer's Disease. Clinics in Geriatric Medicine, 1994, 10, 339-350.	1.0	7
48	Neuropathological processes in Alzheimer's disease. Drug Development Research, 1985, 5, 59-68.	1.4	6
49	Progress in the Management of Alzheimer's Disease. Hospital Practice (1995), 1998, 33, 151-166.	0.5	5
50	Ekosustav bioetike. Jahr, 2017, 8, 227-243.	0.3	4
51	The End of AD Part 3. Alzheimer Disease and Associated Disorders, 2006, 20, 195-198.	0.6	3
52	Involuntary emotional expressive disorder: A case for a deeper neuroethics. Neurotherapeutics, 2007, 4, 560-567.	2.1	3
53	InterWell: an integrated school-based primary care model. London Journal of Primary Care, 2013, 5, 83-7.	0.9	3
54	Regulatory aspects of mild cognitive impairment: toward a harmonized perspective. Dialogues in Clinical Neuroscience, 2004, 6, 409-414.	1.8	2

#	ARTICLE	IF	CITATIONS
55	Managed Care and Complementary and Alternative Medicine: Lessons from the Past and Suggestions for the Future. <i>Journal of Alternative and Complementary Medicine</i> , 1999, 5, 1-2.	2.1	1
56	Public Justice. <i>International Journal of Aging and Human Development</i> , 2014, 80, 95-98.	1.0	1
57	Molecular Approaches to Human Neurological Diseases and Their Animal Models. , 1986, , 171-180.		1
58	Dementia: Nosology and Brain-Behavior Relationships. <i>Dementia and Geriatric Cognitive Disorders</i> , 1991, 2, 116-120.	0.7	0
59	National Institute of Health and Clinical Excellence Decision Processes Supported by UK High Court: The Debate about the Value of Alzheimer's Disease Drugs Continues. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 239-240.	1.2	0
60	The Future of Dementia: A Case of Hardening of the Categories. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 755-758.	0.6	0